DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

24 Drugs in Development

24 Drugs in Development

DIGITAL CONTENT

20 NEWS #PharmaBuzz

media
20 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

24DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Ds-6051b, 1505515-69-4, Taletrectinib adipate, Ds-6051b adipate, 6kll51gnbg, Taletrectinib adipate [usan]

Molecular Formula

C₂₉H₃₄FN₅O₅

Molecular Weight

551.6 g/mol

InChI Key

DORJQZDOULKINH-QNBGGDODSA-N

FDA UNII

6KLL51GNBG

Taletrectinib Adipate is the adiptate form of taletrectinib, a n orally available inhibitor of the receptor tyrosine kinases C-ros oncogene 1 (ROS1) and the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, with potential antineoplastic activity. Upon oral administration, taletrectinib binds to and inhibits ROS1 and the NTRK family members. This inhibition leads to a disruption of ROS1- and NTRK-mediated signaling and eventually inhibits the growth of tumor cells that are overexpressing ROS1 and/or NTRKs. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells. NTRK mutations or rearrangements play a key role in cancer progression.

1 2D Structure

Taletrectinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

3-[4-[(2R)-2-aminopropoxy]phenyl]-N-[(1R)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine;hexanedioic acid

2.1.2 InChI

InChI=1S/C23H24FN5O.C6H10O4/c1-15(25)14-30-20-8-6-17(7-9-20)21-13-26-23-11-10-22(28-29(21)23)27-16(2)18-4-3-5-19(24)12-18;7-5(8)3-1-2-4-6(9)10/h3-13,15-16H,14,25H2,1-2H3,(H,27,28);1-4H2,(H,7,8)(H,9,10)/t15-,16-;/m1./s1

2.1.3 InChI Key

DORJQZDOULKINH-QNBGGDODSA-N

2.1.4 Canonical SMILES

CC(COC1=CC=C(C=C1)C2=CN=C3N2N=C(C=C3)NC(C)C4=CC(=CC=C4)F)N.C(CCC(=O)O)CC(=O)O

2.1.5 Isomeric SMILES

C[C@H](COC1=CC=C(C=C1)C2=CN=C3N2N=C(C=C3)N[C@H](C)C4=CC(=CC=C4)F)N.C(CCC(=O)O)CC(=O)O

2.2 Other Identifiers

2.2.1 UNII

6KLL51GNBG

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 3-(4-((2r)-2-aminopropoxy)phenyl)-n-((1r)-1-(3-fluorophenyl)ethyl)imidazo(1,2-b)pyridazin-6-amine;hexanedioic Acid

2.3.2 Depositor-Supplied Synonyms

1. Ds-6051b

2. 1505515-69-4

3. Taletrectinib Adipate

4. Ds-6051b Adipate

5. 6kll51gnbg

6. Taletrectinib Adipate [usan]

7. 1505515-69-4 (adipate)

8. 3-(4-((r)-2-aminopropoxy)phenyl)-n-((r)-1-(3-fluorophenyl)ethyl)imidazo[1,2-b]pyridazin-6-amine Adipate

9. 3-[4-[((2r)-2-aminopropyl)oxy]phenyl]-n-[(1r)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine Monoadipate

10. 3-[4-[(2r)-2-aminopropoxy]phenyl]-n-[(1r)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine;hexanedioic Acid

11. Unii-6kll51gnbg

12. Ab-106 Adipate

13. Chembl4650361

14. Schembl16468541

15. Glxc-25968

16. Ex-a4255

17. S8901

18. Ac-36532

19. Hy-131003

20. Cs-0120270

21. F78020

22. 3-(4-((r)-2-aminopropoxy)phenyl)-n-((r)-1-(3-fluorophenyl)ethyl)imidazo[1,2-b]pyridazin-6-amine (1:1)

23. 8-trifluoromethyl-3-cyclopropylmethyl-7-[(4-(2,4-difluorophenyl)-1-piperazinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine

24. Hexanedioic Acid, Compd. With 3-[4-[(2r)-2-aminopropoxy]phenyl]-n-[(1r)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine (1:1)

2.4 Create Date

2014-01-13

3 Chemical and Physical Properties

Molecular Formula	C₂₉H₃₄FN₅O₅
Molecular Weight	551.6 g/mol
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	12
Exact Mass	551.25439736 g/mol
Monoisotopic Mass	551.25439736 g/mol
Topological Polar Surface Area	152 Å²
Heavy Atom Count	40
Formal Charge	0
Complexity	645
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2